A proof of concept study for the differentiation of SARS-CoV-2, hCoV-NL63, and IAV-H1N1 in vitro cultures using ion mobility spectrometry.
Animals
Antigens, Viral
/ isolation & purification
COVID-19
/ diagnosis
COVID-19 Serological Testing
/ instrumentation
Chlorocebus aethiops
Coronavirus NL63, Human
/ immunology
Diagnosis, Differential
High-Throughput Screening Assays
/ instrumentation
Humans
Influenza A Virus, H1N1 Subtype
/ immunology
Ion Mobility Spectrometry
Point-of-Care Testing
Proof of Concept Study
SARS-CoV-2
/ immunology
Vero Cells
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 10 2021
11 10 2021
Historique:
received:
08
03
2021
accepted:
22
09
2021
entrez:
12
10
2021
pubmed:
13
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Rapid, high-throughput diagnostic tests are essential to decelerate the spread of the novel coronavirus disease 2019 (COVID-19) pandemic. While RT-PCR tests performed in centralized laboratories remain the gold standard, rapid point-of-care antigen tests might provide faster results. However, they are associated with markedly reduced sensitivity. Bedside breath gas analysis of volatile organic compounds detected by ion mobility spectrometry (IMS) may enable a quick and sensitive point-of-care testing alternative. In this proof-of-concept study, we investigated whether gas analysis by IMS can discriminate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from other respiratory viruses in an experimental set-up. Repeated gas analyses of air samples collected from the headspace of virus-infected in vitro cultures were performed for 5 days. A three-step decision tree using the intensities of four spectrometry peaks correlating to unidentified volatile organic compounds allowed the correct classification of SARS-CoV-2, human coronavirus-NL63, and influenza A virus H1N1 without misassignment when the calculation was performed with data 3 days post infection. The forward selection assignment model allowed the identification of SARS-CoV-2 with high sensitivity and specificity, with only one of 231 measurements (0.43%) being misclassified. Thus, volatile organic compound analysis by IMS allows highly accurate differentiation of SARS-CoV-2 from other respiratory viruses in an experimental set-up, supporting further research and evaluation in clinical studies.
Identifiants
pubmed: 34635788
doi: 10.1038/s41598-021-99742-7
pii: 10.1038/s41598-021-99742-7
pmc: PMC8505652
doi:
Substances chimiques
Antigens, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20143Informations de copyright
© 2021. The Author(s).
Références
Clin Infect Dis. 2021 Feb 16;72(4):690-693
pubmed: 32562422
Chembiochem. 2014 May 5;15(7):1040-8
pubmed: 24719290
Essays Biochem. 2016 Jun 30;60(1):111-20
pubmed: 27365041
Analyst. 2015 Mar 7;140(5):1391-410
pubmed: 25465248
Adv Exp Med Biol. 2011;696:191-9
pubmed: 21431559
J Breath Res. 2021 Feb 12;:
pubmed: 33578396
Biomed Chromatogr. 2009 May;23(5):551-6
pubmed: 19039804
Thorax. 2009 Sep;64(9):744-8
pubmed: 19158121
J Breath Res. 2014 Sep;8(3):037110
pubmed: 25189196
Curr Protoc Microbiol. 2008 Nov;Appendix 4:Appendix 4E
pubmed: 19016439
Med Microbiol Immunol. 2021 Feb;210(1):65-72
pubmed: 33452927
J Breath Res. 2016 Apr 08;10(2):026003
pubmed: 27058305
J Breath Res. 2020 Jul 21;14(4):041001
pubmed: 32531777
J Breath Res. 2020 Oct 22;15(1):011001
pubmed: 33089824
Analyst. 2015 Mar 7;140(5):1376-90
pubmed: 25465076
EClinicalMedicine. 2020 Dec;29:100609
pubmed: 33134902
J Breath Res. 2018 Mar 01;12(2):026015
pubmed: 29199638
Vaccine. 2019 Nov 8;37(47):6996-7002
pubmed: 31288997
PLoS Pathog. 2013 May;9(5):e1003311
pubmed: 23675295
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Ann Transl Med. 2016 Apr;4(7):136
pubmed: 27162786
Clin Chem Lab Med. 2009;47(5):550-60
pubmed: 19397483